Education
About Us
Working with TipRanks
Follow Us
BBH - ETF AI Analysis
Top Page
VanEck Biotech ETF (BBH)
Rating:71Outperform
Price Target:―
Positive Factors
Strong Top Holdings
Several key positions, such as Gilead Sciences and Argenx, have delivered strong year-to-date performance, boosting the ETF’s returns.
Focused Sector Exposure
The ETF’s heavy allocation to the health care sector provides targeted exposure to a high-growth industry.
Reasonable Expense Ratio
The fund’s expense ratio is relatively low, making it cost-effective compared to many other specialized ETFs.
Negative Factors
Over-Concentration in Health Care
With nearly all assets in the health care sector, the ETF is highly exposed to risks specific to this industry.
Weak Performance from Key Holding
Regeneron, one of the top holdings, has underperformed year-to-date, which could drag on overall returns.
Limited Geographic Diversification
The ETF is almost entirely invested in U.S. companies, offering little exposure to international markets.
BBH vs. SPDR S&P 500 ETF (SPY)
AUM391.60M
RegionGlobal
Expense Ratio0.35%
Beta0.64
IssuerVanEck
Inception DateDec 20, 2011
Dividend Yield0.64%
Asset ClassEquity
Index TrackedMVIS US Listed Biotech 25
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume10,019
30 Day Avg. Volume8,430
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
210.21Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering25
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
BBH Summary
The VanEck Biotech ETF (BBH) is an investment fund that focuses on the biotechnology sector, which is part of the broader health care industry. It includes companies that are developing innovative drug therapies, genetic research, and advanced medical technologies. Some well-known companies in this ETF are Gilead Sciences and Amgen. Investors might consider BBH for its potential growth, as biotech is driven by scientific breakthroughs and increasing demand for health solutions. However, new investors should be aware that the ETF’s performance can be volatile, as it depends heavily on the success of biotech companies and their research outcomes.
How much will it cost me?The VanEck Biotech ETF (BBH) has an expense ratio of 0.35%, meaning you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average because it’s a sector-focused ETF that targets biotechnology companies, which often require more active management to track this specialized market. It’s important to consider whether the potential growth in this niche sector aligns with your investment goals.
What would affect this ETF?The VanEck Biotech ETF (BBH) could benefit from advancements in biotechnology, such as breakthroughs in drug development and genetic research, as well as increased global demand for innovative health solutions. However, it may face challenges from regulatory hurdles, high research costs, and potential economic downturns that could impact funding for biotech companies. Additionally, changes in interest rates could affect the financial performance of its top holdings like Gilead Sciences and Amgen.
BBH Top 10 Holdings
The VanEck Biotech ETF is riding the wave of innovation in the biotech sector, with standout performers like Regeneron and Insmed driving recent gains thanks to strong revenue growth and pipeline advancements. Argenx and Natera are also contributing positively, showing bullish momentum and promising developments. However, Alnylam Pharma is lagging, weighed down by cash flow challenges and mixed technical signals. The fund is heavily concentrated in health care, particularly biotech, offering a global mix of established players and emerging innovators, making it a high-stakes bet on cutting-edge medical breakthroughs.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Amgen | 13.22% | $51.75M | $177.64B | 21.02% | 77 Outperform | |
| Gilead Sciences | 11.67% | $45.66M | $150.40B | 31.57% | 77 Outperform | |
| Vertex Pharmaceuticals | 9.42% | $36.87M | $115.56B | -1.43% | 78 Outperform | |
| Regeneron | 5.45% | $21.34M | $75.50B | -7.66% | 78 Outperform | |
| Insmed | 5.34% | $20.91M | $43.51B | 170.56% | 56 Neutral | |
| Natera | 5.18% | $20.26M | $33.75B | 42.47% | 68 Neutral | |
| Argenx Se | 5.06% | $19.81M | $55.28B | 44.62% | 79 Outperform | |
| IQVIA Holdings | 4.66% | $18.23M | $38.46B | 11.46% | 77 Outperform | |
| Alnylam Pharma | 4.22% | $16.53M | $60.52B | 78.77% | 60 Neutral | |
| BeOne Medicines | 3.91% | $15.30M | $37.93B | 57.04% | 68 Neutral |
BBH Technical Analysis
Positive
―
Price Trends
181.74
Positive
172.97
Positive
163.29
Positive
Market Momentum
4.35
Positive
63.83
Neutral
65.71
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For BBH, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 191.34, equal to the 50-day MA of 181.74, and equal to the 200-day MA of 163.29, indicating a bullish trend. The MACD of 4.35 indicates Positive momentum. The RSI at 63.83 is Neutral, neither overbought nor oversold. The STOCH value of 65.71 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for BBH.
BBH Peer Comparison
Comparison Results
Performance Comparison
BBH
VanEck Biotech ETF
194.61
28.38
17.07%
CRBN
iShares MSCI ACWI Low Carbon Target ETF
―
―
―
IVES
Dan IVES Wedbush AI Revolution ETF
―
―
―
EIPI
FT Energy Income Partners Enhanced Income ETF
―
―
―
TAN
Invesco Solar ETF
―
―
―
CANC
Tema Oncology ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents